CartiHeal Receives FDA "Breakthrough Device Designation" for the novel Agili-C Implant

Breakthrough Designation Allows Expedited Review KFAR SABA, Israel, Oct. 12, 2020 -- (Healthcare Sales & Marketing Network) -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic... Devices, Regenerative Medicine, Orthopaedic, FDA CartiHeal, Agili-C, osteoarthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news